Market Size of Cell Dissociation Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 0.53 Billion |
| Market Size (2029) | USD 1.08 Billion |
| CAGR (2024 - 2029) | 15.17 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Cell Dissociation Market Analysis
The Cell Dissociation Market size is estimated at USD 0.53 billion in 2024, and is expected to reach USD 1.08 billion by 2029, growing at a CAGR of 15.17% during the forecast period (2024-2029).
The COVID-19 pandemic had a significant impact on the market studied. As most pharmaceutical companies focused on therapeutics for COVID-19 infection, the production of cell dissociation enzymes decreased significantly during the pandemic. However, the market has reached its pre-pandemic nature and is expected to witness strong growth over the forecast period.
Key factors responsible for the market growth include increasing R&D activities in biopharmaceutical companies and favorable funding for cancer research globally.
The increase in research and development spending in the biopharmaceutical sector aided in the market's growth. For example, according to 'The Pharmaceutical Industry and Global Health Facts and Figures 2021' published by the International Federation of Pharmaceutical Manufacturers & Associations, the annual research and development spending of the biopharmaceutical industry has been 7.3 times greater than that of the aerospace and defense, industries, 6.5 times more than that the chemicals industry, and 1.5 times more than that of the software and computer services industry. The report further stated that in, 2022 over USD 202 billion was estimated to be spent worldwide on biopharmaceutical research and development. Hence, with strong investments in R&D activities and a pipeline of therapeutics under development, cell dissociation is expected to grow significantly.
Various companies are investing in the research and development of biopharmaceuticals. For instance, in September 2022, Marinus Pharmaceuticals exercised the first contract option by the Biomedical Advanced Research and Development Authority (BARDA) valued at approximately USD 12.3 million, to support the United States onshoring of the manufacturing capabilities for ganaxolone. Furthermore, the new investments in the research and development of biologics by the major market players increase the research activity in producing new biologics. They are expected to drive the market to grow. For instance, in September 2022, Novartis invested in next-generation biotherapeutics to grow its biologics manufacturing and development operations. Hence, with huge R&D investments, the market studied is expected to grow strongly in the coming years.
However, the high cost of tissue- and cell-based procedures is expected to restrain the market growth over the forecast period.
